Difference between revisions of "Part:BBa K4165086"

Revision as of 14:26, 6 October 2022

SPINT4 (Serine Peptidase Inhibitor Kunitz type 4).

This basic part encodes Human serine protease inhibitor known as SPINT4 which is able to inhibit serine peptidases, like HtrA1 (BBa_K4165004).

Usage and Biology

This type of family encodes for a type of inhibitor that is predicted to be able to inhibit serine proteases and it is predicted also to be located extracellularly . The inhibitor binds to trypsin-like (serine) proteases and since the catalytic core of HtrA1 (BBa_K4165004) is considered as a tyrpsin-like catalytic domain, so this inhibitor also is considered to inhibit the function of HtrA1 [1] - [4].

Sequence and Features

Functional Parameters

GC% Content 58.2%

Isoelectric point (PI) 9.448

Charge at pH 7 8.538

Molecular Weight (Protein) 11.421 kDa

PDB Structure

Only a predicted model (AlphaFold).

AlphaFold: https://alphafold.ebi.ac.uk/entry/Q6UDR6 Molprobity: Clash Score: Ramachandran Favoured: Ramachandran Outliers: Rotamers Outliers: C-beta Deviations: Q-Mean:

                 Figure 1.: A graphical illustration showing the structure of the inhibitor.

References

1 - Frochaux, V., Hildebrand, D., Talke, A., Linscheid, M. W., & Schlüter, H. (2014). Alpha-1-antitrypsin: a novel human high temperature requirement protease A1 (HTRA1) substrate in human placental tissue. PloS one, 9(10), e109483. 2 - Grau, S., Baldi, A., Bussani, R., Tian, X., Stefanescu, R., Przybylski, M., ... & Ehrmann, M. (2005). Implications of the serine protease HtrA1 in amyloid precursor protein processing. Proceedings of the National Academy of Sciences, 102(17), 6021-6026. 3 - Eigenbrot, C., Ultsch, M., Lipari, M. T., Moran, P., Lin, S. J., Ganesan, R., ... & Kirchhofer, D. (2012). Structural and functional analysis of HtrA1 and its subdomains. Structure, 20(6), 1040-1050. 4 - Chen, T. J., Tian, Y. F., Chou, C. L., Chan, T. C., He, H. L., Li, W. S., ... & Lai, H. Y. (2021). High spink4 expression predicts poor outcomes among rectal cancer patients receiving CCRT. Current Oncology, 28(4), 2373-2384.